Novartis takes oncology Nanobody from Ablynx into the clinic
This article was originally published in Scrip
Executive Summary
Belgium company Ablynx reports that its partner Novartis has begun Phase I testing of a Nanobody drug candidate, the first oncology-focused Nanobody to enter the clinic, and the first development candidate emerging from the licensing agreement between the companies.